Aripiprazole was initially approved to treat schizophrenia and later approved for bipolar
mania, as a monotherapy and an adjunctive therapy (manic or mixed episodes), and for …

There is still considerable controversy about the onset and time course of improvement with
antidepressants in the treatment of major depressive disorder. Previous studies suggested a …

Rationale Premature discontinuation of antidepressant drugs is a frequent clinical problem.
Adverse effects are common, occur early on in treatment and are reported to be one of the …

Background Transcranial direct current stimulation (tDCS) can be an effective treatment for
depression, however, the duration of the stimulation session, among other parameters …

Objectives The therapeutic effects of transcranial magnetic stimulation (TMS) and
transcranial direct current stimulation in patients with major depression have shown …

The introduction of fluoxetine in 1987 marked the arrival of the selective serotonin reuptake
inhibitors (SSRIs) for the treatment for depression. In the United States antidepressant …

Objective Pharmacogenomic-based antidepressant treatment (PGATx) may result in more
precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy …

Objective: To provide clinically relevant evidence‐based recommendations for the
management of depression in adults that are informative, easy to assimilate and facilitate …

In The Lancet Psychiatry, David Nutt and colleagues1 stated that headlines such as
“Antidepressants do more harm than good” plumb a “new nadir in irrational polemic.” I …

Because considerable variability exists between countries in the management of major
depressive disorder, experts in psychiatry gathered for the International Consensus Group …